Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Current Leases (2022 - 2026)

MoonLake Immunotherapeutics' Current Leases history spans 5 years, with the latest figure at $920000.0 for Q1 2026.

  • Quarterly Current Leases fell 35.75% to $920000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $920000.0 through Mar 2026, down 35.75% year-over-year, with the annual reading at $1.2 million for FY2025, 10.06% down from the prior year.
  • Current Leases came in at $920000.0 for Q1 2026, down from $1.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.5 million in Q2 2025 to a low of $153629.0 in Q4 2022.
  • The 5-year median for Current Leases is $1.3 million (2024), against an average of $992805.9.
  • Year-over-year, Current Leases skyrocketed 824.21% in 2024 and then plummeted 35.75% in 2026.
  • MoonLake Immunotherapeutics' Current Leases stood at $153629.0 in 2022, then soared by 679.72% to $1.2 million in 2023, then rose by 14.54% to $1.4 million in 2024, then fell by 10.06% to $1.2 million in 2025, then fell by 25.45% to $920000.0 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Current Leases are $920000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.5 million (Q3 2025).